Robert M, Gagnon C
Urology Research Laboratory, Royal Victoria Hospital, Montréal, Québec, Canada.
Biol Reprod. 1996 Oct;55(4):813-21. doi: 10.1095/biolreprod55.4.813.
Human seminal plasma contains a sperm motility inhibitor that originates from seminal vesicles as a precursor form. This precursor is degraded into smaller peptides by prostatic proteases shortly after ejaculation. The seminal plasma sperm motility inhibitor (SPMI) precursor was purified by a combination of cation-exchange chromatography on S-Sepharose followed by C4 reverse-phase high-performance liquid chromatography directly from seminal vesicle fluid or washed seminal coagulum. The purification procedure yielded a protein of apparent homogeneity, with a molecular mass of 52 kDa by SDS-PAGE. It migrated as a 105-kDa protein by molecular sieving under denaturing conditions. The purified SPMI precursor was digested by the prostatic protease prostate-specific antigen (PSA), causing a 76 +/- 4% drop in biological activity and transformation into low molecular mass SPMI polypeptides (5-20 kDa) similar to those observed in liquefied semen. The N-terminal amino acid sequences of three degradation peptides were obtained by Edman degradation and found to correspond to residues 45-50, 85-90, and 137-143 of semenogelin, a protein characterized as the major structural component of semen coagulum. The amino acid composition of SPMI precursor was found to be almost identical to that of semenogelin. Moreover, the mass of the precursor was estimated at 49,620 daltons by electrospray-ionization mass spectrometry, a value in close agreement with the expected mass of semenogelin according to its cDNA sequence. The SPMI precursor was found to inhibit sperm motility in a dose-dependent manner, with complete immobilization at 500 U/ml of SPMI. The motility of completely immobilized spermatozoa was partially recovered after washing of the cells. The results suggest that SPMI precursor is the major component of the seminal vesicle secretions and seminal coagulum. It can be degraded by PSA in a manner reminiscent of its processing in whole semen. Taken together these results indicate that the SPMI precursor is semenogelin and that intact semenogelin can immobilize spermatozoa.
人类精浆中含有一种精子活力抑制剂,它以前体形式起源于精囊。这种前体在射精后不久被前列腺蛋白酶降解为较小的肽段。精浆精子活力抑制剂(SPMI)前体通过在S-Sepharose上进行阳离子交换色谱,然后直接从精囊液或洗涤后的精液凝块中进行C4反相高效液相色谱的组合进行纯化。纯化过程产生了一种表观均一的蛋白质,通过SDS-PAGE测定其分子量为52 kDa。在变性条件下通过分子筛法测定其迁移率为105 kDa的蛋白质。纯化的SPMI前体被前列腺蛋白酶前列腺特异性抗原(PSA)消化,导致生物活性下降76±4%,并转化为低分子量的SPMI多肽(5-20 kDa),类似于在液化精液中观察到的那些多肽。通过埃德曼降解法获得了三种降解肽的N端氨基酸序列,发现它们对应于精液凝块的主要结构成分——精蛋白的45-50、85-90和137-143位残基。发现SPMI前体的氨基酸组成与精蛋白几乎相同。此外,通过电喷雾电离质谱法估计前体的质量为49,620道尔顿,该值与根据其cDNA序列预期的精蛋白质量密切一致。发现SPMI前体以剂量依赖的方式抑制精子活力,在500 U/ml的SPMI时完全固定。完全固定的精子细胞在洗涤后其活力部分恢复。结果表明,SPMI前体是精囊分泌物和精液凝块的主要成分。它可以被PSA降解,其方式类似于在全精液中的加工过程。综合这些结果表明,SPMI前体是精蛋白,完整的精蛋白可以固定精子。